Citi Maintains Sell Rating on Hospira

Citi is maintaining its Sell rating on shares of Hospira

. “We maintain our Sell rating, as we remain cautious on increasing competitive pressures along with downside risk to 2012 consensus EPS,” Citi writes. “We leave our 2011 $4.04 EPS estimate unchanged though we lower 2H (offset by 2Q) and lower our 2012/2013 by $0.04 each and remain below Street views beyond 2011.” Hospira closed Friday at $55.67.